- Home
- NAN vs GOSS Comparison
NAN vs GOSS Comparison
Compare NAN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAN
- GOSS
- Stock Information
- Founded
- NAN 1999
- GOSS 2015
- Country
- NAN United States
- GOSS United States
- Employees
- NAN N/A
- GOSS N/A
- Industry
- NAN Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NAN Finance
- GOSS Health Care
- Exchange
- NAN Nasdaq
- GOSS Nasdaq
- Market Cap
- NAN 342.0M
- GOSS 347.8M
- IPO Year
- NAN N/A
- GOSS 2019
- Fundamental
- Price
- NAN $10.97
- GOSS $2.47
- Analyst Decision
- NAN
- GOSS Strong Buy
- Analyst Count
- NAN 0
- GOSS 4
- Target Price
- NAN N/A
- GOSS $8.50
- AVG Volume (30 Days)
- NAN 74.6K
- GOSS 3.1M
- Earning Date
- NAN 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- NAN 4.37%
- GOSS N/A
- EPS Growth
- NAN N/A
- GOSS N/A
- EPS
- NAN N/A
- GOSS N/A
- Revenue
- NAN N/A
- GOSS $40,237,000.00
- Revenue This Year
- NAN N/A
- GOSS N/A
- Revenue Next Year
- NAN N/A
- GOSS $30.65
- P/E Ratio
- NAN N/A
- GOSS N/A
- Revenue Growth
- NAN N/A
- GOSS N/A
- 52 Week Low
- NAN $9.11
- GOSS $0.66
- 52 Week High
- NAN $11.34
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- NAN 37.01
- GOSS 68.08
- Support Level
- NAN $10.89
- GOSS $2.38
- Resistance Level
- NAN $10.94
- GOSS $2.65
- Average True Range (ATR)
- NAN 0.06
- GOSS 0.15
- MACD
- NAN -0.00
- GOSS 0.03
- Stochastic Oscillator
- NAN 33.33
- GOSS 76.67
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.